Ecto-NTPDase-Inhibitors – Inhibitors for use in human therapy
The invention provides a new class of nucleosides
exhibiting a high affinity for individual ecto-nucleotidetriphosphate- diphosphohydrolases (E-NTPDases) which have been developed by researchers at the University of Bonn. The inhibitors are capable of inhibiting the metabolization of nucleotides by individual E-NTPDases and thus act as a highly selective indirect agonists of P2- receptors (ATP-, ADP-, UTP-, UDP-receptors). Therapeutic compounds which facilitate the signal transduction via P2-receptors can be used e.g. for the treatment of mucoviscidosis and cancer or for the modulation of inflammatory processes and the immune system. Furthermore, such compounds are valuable tools in biopharmaceutical research. The present invention thus comprises a novel class of therapeutically active compounds as well as methods for preparing the same.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
New insights into sleep
…uncover key mechanisms related to cognitive function. Discovery suggests broad implications for giving brain a boost. While it’s well known that sleep enhances cognitive performance, the underlying neural mechanisms, particularly…
3D-printing advance
… mitigates three defects simultaneously for failure-free metal parts. University of Wisconsin–Madison engineers have found a way to simultaneously mitigate three types of defects in parts produced using a prominent…
Ancient hot water on Mars points to habitable past
Curtin study. New Curtin University-led research has uncovered what may be the oldest direct evidence of ancient hot water activity on Mars, revealing the planet may have been habitable at…